su011248
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
OHSU Knight Cancer InstitutePhase 2Dormant
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Fred Hutchinson Cancer Center | Phase 2 | BB |
Cyclophosphamide OHSU Knight Cancer Institute | Phase 2 | B |
Rapamycin OHSU Knight Cancer Institute | Phase 2 | B |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 2 | B |
Monomethyl Fumarate Fred Hutchinson Cancer Center | Phase 2 | B |
View all 50 →
Same molecule, other indications
su011248 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →